Skip to content

Focal Radiation and low dose skull and spine irradiation followed by chemotherapy for WNT subgroup medulloblastoma

Focal Radiotherapy Plus Low-Dose Craniospinal Irradiation Followed By Adjuvant Chemotherapy in WNT Subgroup Medulloblastoma(FOR-WNT 2 STUDY) - (FOR-WNT 2 STUDY)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/08/027117
Enrollment
30
Registered
2020-08-13
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G938- Other specified disorders of brain

Interventions

Intervention1: Radiotherapy: Planning and treatment Patients shall be immobilized in the supine position using customised thermoplastic mask for head using appropriate head-rest. Care will be taken d

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age more than 3 years and less than 16 years. Newly diagnosed WNT pathway medulloblastoma. Post-surgery residual disease less than 1.5 cm2 on post-operative MRI brain. No evidence of metastatic disease in the brain, spine or cerebral spinal fluid (CSF) assessed by MRI of the brain/spine and lumbar puncture for CSF cytology. Fit for initiation of adjuvant treatment within 6-weeks of surgery

Exclusion criteria

Exclusion criteria: Age Less than 3 and more than 16 years. Molecular subgroup other than WNT pathway. Post-surgery residual disease more than 1.5cm2 on post-operative imaging. Evidence of any metastatic disease in the brain, spine or CSF. Previous history of radiotherapy or chemotherapy prior to study enrollment. Not fit for initiation of adjuvant treatment within 6 weeks of surgery. Not willing for consent/assent.

Design outcomes

Primary

MeasureTime frame
Relapse-free survival Overall survivalTimepoint: 5 year

Secondary

MeasureTime frame
Neurocognitive function Endocrine evaluation Hearing status Prognostic factors for survival Timepoint: 5years

Countries

India

Contacts

Public ContactDr Tejpal Gupta

Tata Memorial Hospital

tejpalgupta@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026